The_DT
Epstein-Barr_JJ
virus_NN
oncoprotein_NN
latent_JJ
membrane_NN
protein_NN
1_CD
engages_VBZ
the_DT
tumor_NN
necrosis_NN
factor_NN
receptor-associated_JJ
proteins_NNS
TRADD_NN
and_CC
receptor-interacting_JJ
protein_NN
-LRB-_-LRB-
RIP_NN
-RRB-_-RRB-
but_CC
does_VBZ
not_RB
induce_VB
apoptosis_NN
or_CC
require_VB
RIP_NN
for_IN
NF-kappaB_NN
activation_NN
._.

A_DT
site_NN
in_IN
the_DT
Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
transforming_VBG
protein_NN
LMP1_NN
that_WDT
constitutively_RB
associates_VBZ
with_IN
the_DT
tumor_NN
necrosis_NN
factor_NN
receptor_NN
1_CD
-LRB-_-LRB-
TNFR1_NN
-RRB-_-RRB-
-_:
associated_VBN
death_NN
domain_NN
protein_NN
TRADD_NN
to_TO
mediate_VB
NF-kappaB_NN
and_CC
c-Jun_NN
N-terminal_JJ
kinase_NN
activation_NN
is_VBZ
critical_JJ
for_IN
long-term_JJ
lymphoblastoid_JJ
cell_NN
proliferation_NN
._.

We_PRP
now_RB
find_VBP
that_IN
LMP1_NN
signaling_NN
through_IN
TRADD_NN
differs_VBZ
from_IN
TNFR1_NN
signaling_NN
through_IN
TRADD_NN
._.

LMP1_NN
needs_VBZ
only_RB
11_CD
amino_NN
acids_NNS
to_TO
activate_VB
NF-kappaB_NN
or_CC
synergize_VB
with_IN
TRADD_NN
in_IN
NF-kappaB_NN
activation_NN
,_,
while_IN
TNFR1_NN
requires_VBZ
approximately_RB
70_CD
residues_NNS
._.

Further_RB
,_,
LMP1_NN
does_VBZ
not_RB
require_VB
TRADD_NN
residues_NNS
294_CD
to_TO
312_CD
for_IN
NF-kappaB_NN
activation_NN
,_,
while_IN
TNFR1_NN
requires_VBZ
TRADD_NN
residues_NNS
296_CD
to_TO
302_CD
._.

LMP1_NN
is_VBZ
partially_RB
blocked_VBN
for_IN
NF-kappaB_NN
activation_NN
by_IN
a_DT
TRADD_NN
mutant_NN
consisting_VBG
of_IN
residues_NNS
122_CD
to_TO
293_CD
._.

Unlike_IN
TNFR1_NN
,_,
LMP1_NN
can_MD
interact_VB
directly_RB
with_IN
receptor-interacting_JJ
protein_NN
-LRB-_-LRB-
RIP_NN
-RRB-_-RRB-
and_CC
stably_RB
associates_VBZ
with_IN
RIP_NN
in_IN
EBV-transformed_JJ
lymphoblastoid_JJ
cell_NN
lines_NNS
._.

Surprisingly_RB
,_,
LMP1_NN
does_VBZ
not_RB
require_VB
RIP_NN
for_IN
NF-kappaB_NN
activation_NN
._.

Despite_IN
constitutive_JJ
association_NN
with_IN
TRADD_NN
or_CC
RIP_NN
,_,
LMP1_NN
does_VBZ
not_RB
induce_VB
apoptosis_NN
in_IN
EBV-negative_JJ
Burkitt_NN
lymphoma_NN
or_CC
human_JJ
embryonic_JJ
kidney_NN
293_CD
cells_NNS
._.

These_DT
results_NNS
add_VBP
a_DT
different_JJ
perspective_NN
to_TO
the_DT
molecular_JJ
interactions_NNS
through_IN
which_WDT
LMP1_NN
,_,
TRADD_NN
,_,
and_CC
RIP_NN
participate_VBP
in_IN
B-lymphocyte_NN
activation_NN
and_CC
growth_NN
._.

